Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A Q3 combination
September 2019
SHARING OPTIONS:

HERTFORDSHIRE, U.K. & PITTSBURGH—Mylan N.V. and Upjohn, Pfizer’s off-patent branded and generic established medicines business, have inked a definitive agreement to combine their companies. Per the agreement—an all-stock, Reverse Morris trust transaction—each Mylan share will be converted into one share of the new company, and following the transaction, Pfizer shareholders will hold 57 percent of the new company, with Mylan shareholders holding 43 percent. The combined company is expected to see pro forma revenues of $19 billion to $20 billion in 2020, with pro forma adjusted EBITDA of roughly $7.5 billion to $8 billion for the year. Leadership will feature board members and executive management members from both Mylan and Upjohn, and the company will be incorporated in Delaware with global centers in Pittsburgh, Shanghai and Hyderabad, India. The transaction is expected to close mid-2020, subject to Mylan shareholder approval and customary closing conditions.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.